Similarities between methamphetamine toxicity and proteasome inhibition

Annals of the New York Academy of Sciences

Volumn 1025, Issue , 2004, Pages 162-170

  Fornai, F ^a,b   Lenzi, P ^a   Gesi, M ^a   Ferrucci, M ^a   Lazzeri, G ^a   Capobianco, L ^b   De Blasi, A ^b   Battaglia, G ^b   Nicoletti, F ^b   Ruggieri, S ^b   Paparelli, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Ist Ricovero Cura Carattere S   (Italy)

Author keywords

Dopamine; Methamphetamine; Neuronal inclusions; Ubiquitin proteasome pathway; Ultrastructure

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; METHAMPHETAMINE; PROTEASOME INHIBITOR; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN NERVE CELL; CELL INCLUSION; CELL ULTRASTRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE METABOLISM; IMMUNOCYTOCHEMISTRY; LEWY BODY; MOUSE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALIA;

EID: 10444238568     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1316.021     Document Type: Conference Paper

References (28)

1. SEIDEN, L.S., R.C. MACPHAIL & M.W. OGLESBY. 1975. Catecholamines and drug-behavior interactions. Fed. Proc. 34: 1823-1831.
2. RICAURTE, G.A. et al. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235: 93-103.
3. WILSON, J.M. et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2: 699-703.
4. SHIMURA, H. et al. 2001. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269.
5. LOWE, J. et al. 1990. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161: 153-160.
6. SPILLANTINI, M.G. et al. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
7. SCHLOSSMACHER, M.G. et al. 2002. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160: 1655-1667.
8. CIECHANOVER, A., A. ORIAN & A.L. SCHWARTZ. 2000. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22: 442-451.
9. BENCE, N.F., R.M. SAMPAT & R.R. KOPITO. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
10. CHUNG, K.K., V.L. DAWSON & T.M. DAWSON. 2001. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24: S7-S14.
11. MCNAUGHT, K.S. et al. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2: 589-594.
12. MCNAUGHT, K.S. et al. 2003. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179: 38-46.
13. KITADA, T. et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
14. LEROY, E. et al. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452.
15. MOURADIAN, M.M. 2002. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology 58: 179-185.
16. CUBELLS, J.F. et al. 1994. Methamphetamine neurotoxity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14: 2260-2271.
17. LARSEN, K.E. et al. 2002. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22: 8951-8960.
18. BATTAGLIA, G. et al. 2002. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22: 2135-2141.
19. FORNAI, F. et al. 1999. Effects of pretreatment with N-(2-chloroethyl)-N- ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72: 777-784.
20. FORNAI, F. et al. 2001. Subcellular localization of a glutathione-dependent dehydroascorbate reductase within specific rat brain regions. Neuroscience 104: 15-31.
21. FORNO, L. 1996. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55: 259-272.
22. SEIDEN, L.S. & G.A. RICAURTE. 1987. Neurotoxicity of methamphetamine and related drugs. In Psychopharmacology: The Third Generation of Progress. H.Y. Meltzer, Ed.: 359-366. Raven Press. New York.
23. CADET, J.L. et al. 1994. Attenuation of methamphetamine-induced neurotoxicity in cupper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62: 380-382.
24. KALANT, H. 2001. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165: 917-928.
25. CONWAY, K.A. et al. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine alpha-synuclein adduct. Science 294: 1257-1258.
26. SULZER, D. 2001. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7: 1280-1282.
27. JAKEL, R.J. & W.F. MARAGOS. 2000. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23: 239-245.
28. FILLOUX, F. & J.J. TOWNSEND. 1993. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119: 79-88.